Biogen CEO Sees Edge Over Lilly With At-Home Alzheimer’s Drug

Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its chief executive officer said in an interview.

Lilly’s drug, Kisunla, launched more than a year after Biogen’s and partner Eisai Co.’s Leqembi, has quickly gained traction. The market for new patients is about evenly split between the two companies.

Now Biogen and Eisai, aiming to maintain their lead, have developed an easier-to-use injection that can be used at home. Last year, US regulators allowed patients to continue on that version of Leqembi on their own after completing ...